Floatz logo

21 assets in AL Amyloidosis

Therapeutic assets addressing AL Amyloidosis, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Dexasone
AL Amyloidosis
St. Olavs HospitalP3BB (66)
Cyclophosphamide
AL Amyloidosis
Alexion Pharmaceuticals, Inc.P3B (60)
Florbetaben
AL Amyloidosis
University of ZurichP3B (60)
Selinexor
AL Amyloidosis
Washington University School of MedicineP2B (58)
Anselamimab
AL Amyloidosis
Alexion Pharmaceuticals, Inc.P3B (57)
Bortezomib
AL Amyloidosis
Alexion Pharmaceuticals, Inc.P3B (57)
Moderna Covid-19 Vaccine Rna
AL Amyloidosis
Barbara Ann Karmanos Cancer InstituteP2CCC (55)
Daratumumab
AL Amyloidosis
Weill Medical College of Cornell UniversityP2CCC (53)
hbi0101 cart
AL Amyloidosis
Polina StepenskyP2CCC (53)
Pomalidomide
AL Amyloidosis
Weill Medical College of Cornell UniversityP2CCC (53)
Siltuximab
AL Amyloidosis
Memorial Sloan Kettering Cancer CenterP2CCC (53)
Teclistamab
AL Amyloidosis
Shanghai Zhongshan HospitalP2CCC (53)
Metabolically Armed Bcma Car-T Cells.
AL Amyloidosis
Anhui Provincial HospitalEarly P1C (39)
Jnj-79635322
AL Amyloidosis
Janssen Research & Development, LLCP1NR ()
Lenalidomide
AL Amyloidosis
Washington University School of MedicineP2NR ()
Linvoseltamab
AL Amyloidosis
Regeneron PharmaceuticalsP1/2NR ()
sar445514
AL Amyloidosis
SanofiP1NR ()